US20220119428A1 - Phospholipidation of imidazoquinolines and oxoadenines - Google Patents

Phospholipidation of imidazoquinolines and oxoadenines Download PDF

Info

Publication number
US20220119428A1
US20220119428A1 US17/566,247 US202117566247A US2022119428A1 US 20220119428 A1 US20220119428 A1 US 20220119428A1 US 202117566247 A US202117566247 A US 202117566247A US 2022119428 A1 US2022119428 A1 US 2022119428A1
Authority
US
United States
Prior art keywords
formula
compound
reacting
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/566,247
Inventor
Helene G. Bazin-Lee
Laura S. BESS
David A. Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to US17/566,247 priority Critical patent/US20220119428A1/en
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA reassignment GLAXOSMITHKLINE BIOLOGICALS SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JOHNSON, DAVID A., BAZIN-LEE, HELENE G., BESS, LAURA S
Publication of US20220119428A1 publication Critical patent/US20220119428A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Definitions

  • the present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)—active and toll-like receptor 8 (TLR8)—active imidazoquinolines and oxoadenines.
  • TLR7 toll-like receptor 7
  • TLR8 toll-like receptor 8
  • TLRs Toll-like receptors
  • IFN ⁇ / ⁇ type I interferons alpha and beta
  • TLR7 and TLR8 activation a few different classes of small-molecule mimetics of the natural uridine- and/or guanosine-rich viral ssRNA ligands have been identified (Heil et al. Eur. J Immunol. 2003, 33, 2987-2997, Hemmi et al. Nat. Immunol. 2002, 3, 196-200, Lee et al. Proc. Natl. Acad Sci. U.S.A. 2006, 103, 1828-1833), including oxoadenine analogs (Hirota et al. J. Med Chem.
  • TLR7 and TLR8 are broadly expressed in dendritic cells (DCs) and other antigen presenting cells, TLR7/8 agonists and their derivatives may be especially useful as vaccine adjuvants.
  • oral and topical preparations of imiquimod and resiquimod and other small-molecule TLR7/8 agonists can exhibit serious side effects, and clinical trials with certain TLR7/8 agonists have been suspended over safety concerns (Horscroft et al. J. Antimicrob. Chemother. 2012, 67, 789-801, Strominger, N. L.; Brady, R.; Gullikson, G.; Carpenter, D. O. Brain Res. Bull. 2001, 55, 445-451).
  • TLR7 and TLR8 are located in endosomal/lysosomal compartments (Lee et al. Proc. Natl. Acad Sci. U.S.A. 2003, 100, 6646-6651), cellular uptake is prerequisite for cellular activation by TLR7/8 ligands.
  • TLR7/8 ligands Lipid conjugation of nucleoside drugs including TLR7/8 agonists (Chan et al. Bioconjugate Chem. 2009, 20, 1194-1200) is one strategy known to facilitate endocytosis, enhance oral bioavailability, and decrease toxic side effects.
  • nucleolipids can also be incorporated into liposomes and other biodegradable nanoparticles to help protect the drug from degradation and further reduce toxicity through a depot effect (Rosemeyer, H. Chemistry & Biodiversity 2005, 2, 977-1063).
  • the present invention relates to a process for preparing compounds of formula (I) and formula (II) that comprises an imidazoquinoline or an oxoadenine molecule covalently linked to a phospho group.
  • R 1 is selected from H, C 1-6 alkyl, C 1-6 alkylamino, C 1-6 alkoxy, C 3-6 cycloalkylC 1-6 alkyl, C 3-6 cycloalkylC 1-6 alkylamino, C 3-6 cycloalkylC 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkylamino and C 1-6 alkoxyC 1-6 alkoxy; wherein the C 1-6 alkyl, C 1-6 alkylamino, C 1-6 alkoxy, C 3-6 cycloalkylC 1-6 alkyl, C 3-6 cycloalkylC 1-6 alkylamino, C 3-6 cycloalkylC 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkylamino or C 1-6 alkoxyC 1-6 alkoxy is branched or unbranched and optionally terminally substituted with
  • Z is selected from C 2 -C 6 alkyl and C 2 -C 6 alkenyl, wherein the C 2 -C 6 alkyl or C 2 -C 6 alkenyl is unsubstituted or terminally substituted by —(O—C 2 -C 6 alkyl) 1-6 -;
  • R 4 is selected from C 1-6 alkyl, C 1-6 alkylamino, C 1-6 alkoxy, C 3-6 cycloalkylC 1-6 alkyl, C 3-6 cycloalkylC 1-6 alkylamino, C 3-6 cycloalkylC 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkylamino and C 1-6 alkoxyC 1-6 alkoxy; wherein the C 1-6 alkyl, C 1-6 alkylamino, C 1-6 alkoxy, C 3-6 cycloalkylC 1-6 alkyl, C 3-6 cycloalkylC 1-6 alkylamino, C 3-6 cycloalkylC 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkylamino or C 1-6 alkoxyC 1-6 alkoxy is branched or unbranched and optionally terminally substituted with a
  • d 0, 1, 2, 3, 4, 5 or 6;
  • Het is a four-, five-, or six membered saturated nitrogen heterocycle wherein
  • n 0, 1, 2, 3, 4, 5 or 6;
  • the present invention provides a process for preparing compounds of formula (I).
  • the process comprises the steps of:
  • the present invention provides another process for preparing a compound of formula (I). This process comprises the steps of:
  • the present invention provides a process for preparing compounds of formula (II).
  • the process comprises the steps of:
  • the present invention provides another process for preparing a compound of formula (II). This process comprises the steps of:
  • a compound of formula (I) means a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • a compound of formula (II) means a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof.
  • a compound of the invention means a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt or solvate thereof.
  • the term “optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) that occur and events that do not occur.
  • Certain compounds of formula (I) or formula (II) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms).
  • the individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention.
  • the present invention also covers the individual isomers of the compounds represented by formula (I) or formula (II) as mixtures with isomers thereof in which one or more chiral centers are inverted.
  • Certain compounds of the invention may exist in tautomeric forms. It will be understood that the present invention encompasses all of the tautomers of the compounds of the invention whether as individual tautomers or as mixtures thereof whether or not explicitly indicated in the present formulas.
  • Suitable pharmaceutically acceptable salts according to the present invention will be readily determined by one skilled in the art and will include, for example, salts prepared from inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, lithium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, as well as potassium tert-butoxide and organic bases such as diethyl amine, lysine, arginine, choline hydroxide, choline bicarbonate, tris (hydroxymethyl) aminomethane (tromethamine), triethanolamine, diethanolamine, and ethanolamine.
  • inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, lithium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, as well as potassium tert-butoxide and organic bases such as diethyl amine, lysine, arginine, choline hydroxide, choline bicarbonate,
  • salts of a compound of formula (I) or formula (II) should be pharmaceutically acceptable, but pharmaceutically unacceptable salts may conveniently be used to prepare the corresponding free base or pharmaceutically acceptable salts thereof.
  • solvate refers to a crystal form containing the compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof and either a stoichiometric or a non-stoichiometric amount of a solvent.
  • Solvents include water (thus producing hydrates), methanol, ethanol, or acetic acid.
  • reference to a compound of formula (I) or formula (II) is to any physical form of that compound, unless a particular form, salt or solvate thereof is specified.
  • the compounds of the invention of formula (I) or formula (II) may be in crystalline or amorphous form. Furthermore, some of the crystalline forms of the compounds of the invention may exist as polymorphs, all of which are included within the scope of the present invention. The most thermodynamically stable polymorphic form or forms of the compounds of the invention are of particular interest.
  • Polymorphic forms of compounds of the invention may be characterised and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD), infrared spectroscopy (IR), Raman spectroscopy, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and solid-state nuclear magnetic resonance (ssNMR).
  • XRPD X-ray powder diffraction
  • IR infrared spectroscopy
  • Raman spectroscopy Raman spectroscopy
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • ssNMR solid-state nuclear magnetic resonance
  • a compound of formula (I) or formula (II) may be prepared using the processes depicted below.
  • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
  • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
  • the compound of formula (VI) or (VI)′′ may be prepared by reacting the compound of formula (III) or (IV) with a of formula (V) in the presence of a suitable phosphoramidite coupling reagent such as 1H-tetrazole, substituted terazole, dicyanoimidazole, imidazolium triflate or any such coupling reagents known to those skilled in the art, in an aprotic solvent such as but not limited to methylene chloride, between 0° C. and ambient temperature.
  • a suitable phosphoramidite coupling reagent such as 1H-tetrazole, substituted terazole, dicyanoimidazole, imidazolium triflate or any such coupling reagents known to those skilled in the art, in an aprotic solvent such as but not limited to methylene chloride, between 0° C. and ambient temperature.
  • the compound of formula (VI) or (VI)′′ which may be purified by chromatography on silica gel but is preferably not isolated or purified, may be directly reacted upon formation with compound of formula (VII) or (VIII) in the presence of a suitable phosphoramidite coupling reagent such as 1H-tetrazole, substituted tetrazole, dicyanoimidazole, imidazolium triflate or any such coupling reagents known to those skilled in the art, in an aprotic solvent such as but not limited to methylene chloride, between 0° C. and ambient temperature to prepare compounds of formula (IX), (IX)′′, (IX)* and (IX)*′′.
  • a suitable phosphoramidite coupling reagent such as 1H-tetrazole, substituted tetrazole, dicyanoimidazole, imidazolium triflate or any such coupling reagents known to those skilled in the art
  • the compound of formula (IX), (IX)′′, (IX)* or (IX)*′′ is converted to a compound of formula (I) or formula (II) by oxidation using phosphorus oxidizing agent such as but not limited to m-chloroperbenzoic acid, hydrogen peroxide, iodine/pyridine/water, or tert-butylperoxide followed by removal of the protecting group using techniques known to those skilled in the art.
  • phosphorus oxidizing agent such as but not limited to m-chloroperbenzoic acid, hydrogen peroxide, iodine/pyridine/water, or tert-butylperoxide followed by removal of the protecting group using techniques known to those skilled in the art.
  • compounds of formula (I) or formula (II) are prepared by:
  • 1H-tetrazole is added to a compound of formula (III) or formula (IV) in ⁇ 30 min (for example, 4 portions; for example, one added every ten minutes).
  • ⁇ 30 min means + or ⁇ 10 minutes, 20-40 minutes.
  • a compound of formula (V) is added and reacted with a compound of formula (III) or a compound of formula (IV), forming a compound of formula (VI) or (VI)′′, to which a compound of formula (VII) or formula (VIII) is added before the addition of imidazolium triflate.
  • reaction mixture containing the compound of formula (VI) or (VI)′′ is cooled to 0° C. before the addition of a compound of formula (VII) or formula (VIII).
  • the protecting group is cyanoethyl.
  • deprotection is performed with triethylamine (TEA).
  • TAA triethylamine
  • the protecting group is cyanoethyl and deprotection is with triethylamine (TEA).
  • TAA triethylamine
  • the coupling agent used with a compound of formula (III) or formula (IV) and a compound of formula (V) is at 2.1 equivalents, the compound of formula (III) or formula (IV) is at 2.0 equivalents, the compound of formula (V) is at 2.1 equivalents, the compound of formula (VII) or formula (VIII) is at 1.0 equivalent and the oxidizing agent for the compound of formula (IX), (IX)′′, (IX)* or (IX)*′′ is at 1.5 equivalent.
  • imidazolium triflate is added with the compound of formula (VII) or the compound of formula (VIII) to the same reaction mixture produced by the reaction of compound of formula (V) with the compound of formula (III) or the compound of formula (IV).
  • ES TOF-MS electrospray time of flight mass spectroscopy
  • NMR nuclear magnetic resonance
  • TEA triethylamine
  • the reaction mixture was allowed to warm up to rt.
  • the reaction was usually completed after 1 hour at rt.
  • the resulting phosphite IX, IX′′, IX* or IX*′′ can be purified at this stage or subsequently oxidized without isolation.
  • the phosphotriester IX, IX′′, IX* or IX*′′ (purified or not) in a solution of methylene chloride was oxidized by addition of t-butyl hydroperoxide (1.5 eq) to the reaction mixture and stirring at rt for 30 min. After completion of the oxidation, the reaction mixture was concentrated under vacuum and purified by chromatography on silica gel. The resulting protected phosphotriester was dissolved in acetonitrile (0.06 M). Triethylamine (acetonitrile:TEA 1:0.35 v:v) was added and the reaction mixture stirred at rt for 6 to 18 hours. Once the deprotection was complete, the reaction mixture was filtered over a Buchner filter and the isolated solid rinsed with acetonitrile and dried under high vacuum. The reaction mixture can also be purified by chromatography on silica gel.
  • Phosphotriester IXa was prepared in 93% yield by reacting di-O-palmitoyl glycerol IIa with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXa was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ia in 71% yield.
  • Phosphotriester IXb was prepared in 99% yield by reacting di-O-palmitoyl glycerol IIIa with V followed by addition of imidazoquinoline VIIb and imidazolium triflate as described in example 1. IXb was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ib in 73% yield.
  • Phosphotriester IXc was prepared in 97% yield by reacting di-O-hexadecyl glycerol IIIc with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXc was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ic in 71% yield.
  • Phosphotriester IXd was prepared in 79% yield by reacting di-O-lauroyl glycerol IIId with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXd was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Id in 77% yield.
  • Phosphotriester IXe was prepared in 62% yield by reacting di-O-myristoyl glycerol IIe with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXe was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ie in 89% yield.
  • Phosphotriester IXf was prepared in 92% yield by reacting di-O-oleoyl glycerol IIIf with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXf was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline If in 75% yield.
  • Phosphotriester IX′′a was prepared in 99% yield by reacting ethyl cholesterol IVa with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IX′′a was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ig in 44% yield.
  • Phosphotriester IX′′b was prepared in 96% yield by reacting butyl cholesterol IVb with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IX′′b was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ih in 56% yield.
  • Phosphotriester IX*a was prepared in 33% yield by reacting di-O-palmitoyl glycerol IIIa with V followed by addition of oxoadenine VIIIa and imidazolium triflate as described in example 1. IX*a was oxidized and deprotected following the procedure described in example 2 to give phospholipidated oxoadenine IIa in 56% yield.
  • Phosphotriester IX*b was prepared in 58% yield by reacting di-O-oeloyl glycerol IIIf with V followed by addition of oxoadenine VIIIa and imidazolium triflate as described in example 1. IX*b was oxidized and deprotected following the procedure described in example 2 to give phospholipidated oxoadenine IIb in 73% yield.

Abstract

The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)—active and toll-like receptor (TLR8)—active imidazoquinolines and oxoadenines.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation of copending U.S. application Ser. No. 16/989,235 filed on Aug. 10, 2020, which is a Continuation of U.S. application Ser. No. 16/060,142 filed on Jun. 7, 2018, now U.S. Pat. No. 10,774,099, issued on Sep. 15, 2020, which is a National Phase of PCT International Application No. PCT/EP2016/080647 filed on Dec. 12, 2016, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/266,858, filed on Dec. 14, 2015, all of which are hereby expressly incorporated by reference into the present application.
    • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
  • This invention was made with Government support under contract #HHSN272200900036C awarded by the National Institutes of Health. The Government has certain rights in the invention.
    • BACKGROUND OF THE INVENTION
  • The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)—active and toll-like receptor 8 (TLR8)—active imidazoquinolines and oxoadenines.
  • Toll-like receptors (TLRs) are a family of more than 10 structurally related receptors on innate immune cells that detect pathogen-specific components common to large classes of microbial invaders. Activation of these receptors leads to the expression of inflammatory cytokines/chemokines and type I interferons alpha and beta (IFNα/β) important for effective innate and adaptive immune responses to infectious disease and cancer.
  • In the case of TLR7 and TLR8 activation, a few different classes of small-molecule mimetics of the natural uridine- and/or guanosine-rich viral ssRNA ligands have been identified (Heil et al. Eur. J Immunol. 2003, 33, 2987-2997, Hemmi et al. Nat. Immunol. 2002, 3, 196-200, Lee et al. Proc. Natl. Acad Sci. U.S.A. 2006, 103, 1828-1833), including oxoadenine analogs (Hirota et al. J. Med Chem. 2002, 45, 5419; WO 2007/034882 PCT/JP2006/318758, Dainippon Sumitomo Pharma Co. Ltd./AstraZeneca Aktiebolag) and 1H-imidazo[4,5-c]quinolines (Gerster et al. J. Med Chem. 2005, 48, 3481-3491) such as imiquimod, which is approved for topical treatment of certain skin diseases and known to primarily activate TLR7, and the structurally related imidazoquinoline resiquimod, which potently activates both TLR7 and TLR8 (Miller et al. Drug News Perspect. 2008, 21, 69-87).
  • Since TLR7 and TLR8 are broadly expressed in dendritic cells (DCs) and other antigen presenting cells, TLR7/8 agonists and their derivatives may be especially useful as vaccine adjuvants. However, oral and topical preparations of imiquimod and resiquimod and other small-molecule TLR7/8 agonists can exhibit serious side effects, and clinical trials with certain TLR7/8 agonists have been suspended over safety concerns (Horscroft et al. J. Antimicrob. Chemother. 2012, 67, 789-801, Strominger, N. L.; Brady, R.; Gullikson, G.; Carpenter, D. O. Brain Res. Bull. 2001, 55, 445-451). In addition, since TLR7 and TLR8 are located in endosomal/lysosomal compartments (Lee et al. Proc. Natl. Acad Sci. U.S.A. 2003, 100, 6646-6651), cellular uptake is prerequisite for cellular activation by TLR7/8 ligands. Thus, there is considerable interest in strategies that will increase the penetration of the TLR7/8 ligand into DCs and other immune cells as well as ameliorate toxic effects. Lipid conjugation of nucleoside drugs including TLR7/8 agonists (Chan et al. Bioconjugate Chem. 2009, 20, 1194-1200) is one strategy known to facilitate endocytosis, enhance oral bioavailability, and decrease toxic side effects. Such nucleolipids can also be incorporated into liposomes and other biodegradable nanoparticles to help protect the drug from degradation and further reduce toxicity through a depot effect (Rosemeyer, H. Chemistry & Biodiversity 2005, 2, 977-1063).
    • SUMMARY OF THE INVENTION
  • The present invention relates to a process for preparing compounds of formula (I) and formula (II) that comprises an imidazoquinoline or an oxoadenine molecule covalently linked to a phospho group.
  • Figure US20220119428A1-20220421-C00001
  • wherein
  • R1 is selected from H, C1-6alkyl, C1-6alkylamino, C1-6alkoxy, C3-6cycloalkylC1-6alkyl, C3-6cycloalkylC1-6alkylamino, C3-6cycloalkylC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkylamino and C1-6alkoxyC1-6alkoxy; wherein the C1-6alkyl, C1-6alkylamino, C1-6alkoxy, C3-6cycloalkylC1-6alkyl, C3-6cycloalkylC1-6alkylamino, C3-6cycloalkylC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkylamino or C1-6alkoxyC1-6alkoxy is branched or unbranched and optionally terminally substituted with a hydroxyl, amino, thio, hydrazino, hydrazido, azido, acetylenyl, carboxyl, or maleimido group;
  • Z is selected from C2-C6 alkyl and C2-C6 alkenyl, wherein the C2-C6 alkyl or C2-C6 alkenyl is unsubstituted or terminally substituted by —(O—C2-C6alkyl)1-6-;
  • A is
  • Figure US20220119428A1-20220421-C00002
      • wherein
      • R2 is H or a straight or branched, optionally unsaturated, C4-C24 alkyl, or a straight or branched, optionally unsaturated, C4-C24 acyl;
      • R3 is a straight or branched, optionally unsaturated, C4-C24 alkyl or a straight or branched, optionally unsaturated, C4-C24 acyl;
      • n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
  • Figure US20220119428A1-20220421-C00003
  • wherein
  • R4 is selected from C1-6alkyl, C1-6alkylamino, C1-6alkoxy, C3-6cycloalkylC1-6alkyl, C3-6cycloalkylC1-6alkylamino, C3-6cycloalkylC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkylamino and C1-6alkoxyC1-6alkoxy; wherein the C1-6alkyl, C1-6alkylamino, C1-6alkoxy, C3-6cycloalkylC1-6alkyl, C3-6cycloalkylC1-6alkylamino, C3-6cycloalkylC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkylamino or C1-6alkoxyC1-6alkoxy is branched or unbranched and optionally terminally substituted with a hydroxyl, amino, thio, hydrazino, hydrazido, azido, acetylenyl, carboxyl, or maleimido group;
  • d is 0, 1, 2, 3, 4, 5 or 6;
  • Het is a four-, five-, or six membered saturated nitrogen heterocycle wherein
      • X,Y═CH or N, and at least one of X and Y is a nitrogen atom;
  • m is 0, 1, 2, 3, 4, 5 or 6;
  • A is
  • Figure US20220119428A1-20220421-C00004
      • wherein
      • R2 is H or a straight or branched, optionally unsaturated, C4-C24 alkyl, or a straight or branched, optionally unsaturated, C4-C24 acyl;
      • R3 is a straight or branched, optionally unsaturated, C4-C24 alkyl or a straight or branched, optionally unsaturated, C4-C24 acyl;
      • n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
  • As a first aspect, the present invention provides a process for preparing compounds of formula (I). The process comprises the steps of:
  • a) reacting a compound of formula (III)
  • Figure US20220119428A1-20220421-C00005
      • with a compound of formula (V)
  • Figure US20220119428A1-20220421-C00006
      • wherein
      • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
      • all other variables are as defined above for formula (I);
  • to prepare a compound of formula (VI)
  • Figure US20220119428A1-20220421-C00007
      • wherein
      • R is
  • Figure US20220119428A1-20220421-C00008
      • all other variables are as defined above for formula (I);
  • b) reacting a compound of formula (VI) with a compound of formula (VII)
  • Figure US20220119428A1-20220421-C00009
  • to prepare a compound of formula (IX)
  • Figure US20220119428A1-20220421-C00010
      • wherein
      • R is
  • Figure US20220119428A1-20220421-C00011
      • R′ is
  • Figure US20220119428A1-20220421-C00012
      • and all other variables are as defined above for formula (I);
  • c) oxidizing a compound of formula (IX) and removing the hydroxyl protecting group to obtain a compound of formula (I).
  • In another aspect, the present invention provides another process for preparing a compound of formula (I). This process comprises the steps of:
  • a) reacting a compound of formula (IV)
  • Figure US20220119428A1-20220421-C00013
      • with a compound of formula (V)
  • Figure US20220119428A1-20220421-C00014
      • wherein
      • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group; and
      • all other variables are as defined above for formula (I);
  • to prepare a compound of formula (VI)″;
  • Figure US20220119428A1-20220421-C00015
      • wherein
      • R″ is
  • Figure US20220119428A1-20220421-C00016
      • all other variables are as defined above for formula (I);
  • b) reacting a compound of formula (VI)″ with a compound of formula (VII)
  • Figure US20220119428A1-20220421-C00017
  • to prepare a compound of formula (IX)″;
  • Figure US20220119428A1-20220421-C00018
      • wherein
      • R″ is
  • Figure US20220119428A1-20220421-C00019
  • R′ is
  • Figure US20220119428A1-20220421-C00020
      • all other variables are as defined above for formula (I);
  • c) oxidizing a compound of formula (IX)″ and removing the hydroxyl protecting group to obtain a compound of formula (I).
  • In a third aspect, the present invention provides a process for preparing compounds of formula (II). The process comprises the steps of:
  • a) reacting a compound of formula (III)
  • Figure US20220119428A1-20220421-C00021
      • with a compound of formula (V)
  • Figure US20220119428A1-20220421-C00022
      • wherein
      • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
      • all other variables are as defined above for formula (II);
  • Figure US20220119428A1-20220421-C00023
  • to prepare a compound of formula (VI) (VI)
      • wherein
      • R is
  • Figure US20220119428A1-20220421-C00024
      • all other variables are as defined above for formula (II);
  • b) reacting a compound of formula (VI) with a compound of formula (VIII)
  • Figure US20220119428A1-20220421-C00025
  • to prepare a compound of formula (IX)*
  • Figure US20220119428A1-20220421-C00026
      • wherein
      • R is
  • Figure US20220119428A1-20220421-C00027
      • R* is
  • Figure US20220119428A1-20220421-C00028
      • all other variables are as defined above for formula (II);
  • c) oxidizing a compound of formula (IX)* and removing the hydroxyl protecting group to obtain a compound of formula (II).
  • In a forth aspect, the present invention provides another process for preparing a compound of formula (II). This process comprises the steps of:
  • a) reacting a compound of formula (IV)
  • Figure US20220119428A1-20220421-C00029
      • with a compound of formula (V)
  • Figure US20220119428A1-20220421-C00030
      • wherein
      • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
      • all other variables are as defined above for formula (II);
  • to prepare a compound of formula (VI)″;
  • Figure US20220119428A1-20220421-C00031
      • wherein
      • R″ is
  • Figure US20220119428A1-20220421-C00032
      • all other variables are as defined above for formula (II);
  • b) reacting a compound of formula (VI)″ with a compound of formula (VIII)
  • Figure US20220119428A1-20220421-C00033
  • to prepare a compound of formula (IX)*″;
  • Figure US20220119428A1-20220421-C00034
  • wherein
      • R″ is
  • Figure US20220119428A1-20220421-C00035
      • R*is
  • Figure US20220119428A1-20220421-C00036
      • all other variables are as defined above for formula (II);
  • c) oxidizing a compound of formula (IX)*″ and removing the hydroxyl protecting group to obtain a compound of formula (II).
  • Further aspects of the present invention are described in the description of particular embodiments, examples, and claims which follow.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • As used herein, “a compound of formula (I)” means a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. “A compound of formula (II)” means a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof.
  • As used herein, “a compound of the invention” means a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt or solvate thereof.
  • As used herein, the term “optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) that occur and events that do not occur.
  • Certain compounds of formula (I) or formula (II) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention. The present invention also covers the individual isomers of the compounds represented by formula (I) or formula (II) as mixtures with isomers thereof in which one or more chiral centers are inverted.
  • Certain compounds of the invention may exist in tautomeric forms. It will be understood that the present invention encompasses all of the tautomers of the compounds of the invention whether as individual tautomers or as mixtures thereof whether or not explicitly indicated in the present formulas.
  • Suitable pharmaceutically acceptable salts according to the present invention will be readily determined by one skilled in the art and will include, for example, salts prepared from inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, lithium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, as well as potassium tert-butoxide and organic bases such as diethyl amine, lysine, arginine, choline hydroxide, choline bicarbonate, tris (hydroxymethyl) aminomethane (tromethamine), triethanolamine, diethanolamine, and ethanolamine.
  • When used in medicine, the salts of a compound of formula (I) or formula (II) should be pharmaceutically acceptable, but pharmaceutically unacceptable salts may conveniently be used to prepare the corresponding free base or pharmaceutically acceptable salts thereof.
  • As used herein, the term “solvate” refers to a crystal form containing the compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof and either a stoichiometric or a non-stoichiometric amount of a solvent. Solvents, by way of example, include water (thus producing hydrates), methanol, ethanol, or acetic acid. Hereinafter, reference to a compound of formula (I) or formula (II) is to any physical form of that compound, unless a particular form, salt or solvate thereof is specified.
  • Processes for preparing pharmaceutically acceptable salts of the compounds of formula (I) or formula (II) are conventional in the art. See, e.g., Burger's Medicinal Chemistry And Drug Discovery 5th Edition, Vol 1: Principles And Practice.
  • The compounds of the invention of formula (I) or formula (II) may be in crystalline or amorphous form. Furthermore, some of the crystalline forms of the compounds of the invention may exist as polymorphs, all of which are included within the scope of the present invention. The most thermodynamically stable polymorphic form or forms of the compounds of the invention are of particular interest.
  • Polymorphic forms of compounds of the invention may be characterised and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD), infrared spectroscopy (IR), Raman spectroscopy, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and solid-state nuclear magnetic resonance (ssNMR).
  • It will be appreciated from the foregoing that included within the scope of the invention are solvates, isomers and polymorphic forms of the compounds of formula (I) and formula (II) and salts thereof.
  • A compound of formula (I) or formula (II) may be prepared using the processes depicted below.
  • Figure US20220119428A1-20220421-C00037
  • wherein
  • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
  • R is
  • Figure US20220119428A1-20220421-C00038
  • R′ is
  • Figure US20220119428A1-20220421-C00039
  • all other variables are as defined above for formula (I).
  • In general, the process for preparing a compound of formula (I) as depicted in Scheme 1 comprises the steps of:
  • a) reacting a compound of formula (III) with a compound of formula (V) to prepare a compound of formula (VI);
  • b) reacting a compound of formula (VI) with a compound of formula (VII) to to prepare a compound of formula (IX); and
  • c) oxidizing a compound of formula (IX) and removing the hydroxyl protecting group to obtain a compound of formula (I).
  • Figure US20220119428A1-20220421-C00040
  • wherein
  • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
  • R″ is
  • Figure US20220119428A1-20220421-C00041
  • R′ is
  • Figure US20220119428A1-20220421-C00042
  • and
  • all other variables are as defined above for formula (I);
  • In general, the process for preparing a compound of formula (I) as depicted in Scheme 2 comprises the steps of:
  • a) reacting a compound of formula (IV) with a compound of formula (V) to prepare a compound of formula (VI)″;
  • b) reacting a compound of formula (VI)″ with a compound of formula (VII) to prepare a compound of formula (IX)″; and
  • c) oxidizing a compound of formula (IX)″ and removing the hydroxyl protecting group to obtain a compound of formula (I).
  • Figure US20220119428A1-20220421-C00043
      • wherein
      • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
      • R is
  • Figure US20220119428A1-20220421-C00044
      • R* is
  • Figure US20220119428A1-20220421-C00045
      • all other variables are as defined above for formula (II).
  • In general, the process for preparing a compound of formula (II) as depicted in Scheme 3 comprises the steps of:
  • a) reacting a compound of formula (III) with a compound of formula (V) to prepare a compound of formula (VI); and
  • b) reacting a compound of formula (VI) with a compound of formula (VIII) to prepare a compound of formula (IX)*; and
  • c) oxidizing a compound of formula (IX)* and removing the hydroxyl protecting group to obtain a compound of formula (II).
  • Figure US20220119428A1-20220421-C00046
      • wherein
      • PG is a protecting group suitable for hydroxyl protection, including but not limited to cyanoethyl, methyl, ethyl, benzyl and allyl group;
      • R″ is
  • Figure US20220119428A1-20220421-C00047
      • R* is
  • Figure US20220119428A1-20220421-C00048
      • all other variables are as defined above for formula (II).
  • In general, the process for preparing a compound of formula (II) as depicted in Scheme 4 comprises the steps of:
  • a) reacting a compound of formula (IV) with a compound of formula (V) to prepare a compound of formula (VI)″;
  • b) reacting a compound of formula (VI)″ with a compound of formula (VIII) to prepare a compound of formula (IX)*″;
  • c) oxidizing a compound of formula (IX)*″ and removing the hydroxyl protecting group to obtain a compound of formula (II).
  • More particularly, the compound of formula (VI) or (VI)″ may be prepared by reacting the compound of formula (III) or (IV) with a of formula (V) in the presence of a suitable phosphoramidite coupling reagent such as 1H-tetrazole, substituted terazole, dicyanoimidazole, imidazolium triflate or any such coupling reagents known to those skilled in the art, in an aprotic solvent such as but not limited to methylene chloride, between 0° C. and ambient temperature.
  • The compound of formula (VI) or (VI)″, which may be purified by chromatography on silica gel but is preferably not isolated or purified, may be directly reacted upon formation with compound of formula (VII) or (VIII) in the presence of a suitable phosphoramidite coupling reagent such as 1H-tetrazole, substituted tetrazole, dicyanoimidazole, imidazolium triflate or any such coupling reagents known to those skilled in the art, in an aprotic solvent such as but not limited to methylene chloride, between 0° C. and ambient temperature to prepare compounds of formula (IX), (IX)″, (IX)* and (IX)*″.
  • The compound of formula (IX), (IX)″, (IX)* or (IX)*″ is converted to a compound of formula (I) or formula (II) by oxidation using phosphorus oxidizing agent such as but not limited to m-chloroperbenzoic acid, hydrogen peroxide, iodine/pyridine/water, or tert-butylperoxide followed by removal of the protecting group using techniques known to those skilled in the art.
  • In one embodiment, compounds of formula (I) or formula (II) are prepared by:
      • (i) adding 1H-tetrazole (2.1 eq) in several portions to a methylene chloride solution of a compound of formula (III) or formula (IV) (2.0 eq) followed by the phosphordiamidite reagent of formula (V) (2.1 eq) and reacting 30 min to 1 h at room temperature after the last addition of tetrazole,
      • (ii) cooling the reaction mixture to 0° C.,
      • (iii) adding a compound of formula (VII) or (VIII) (1.0 eq) and imidazolium triflate (1.5 eq), and reacting at 0° C. for up to 30 min then at room temperature for 1 hour to 24 hours, and
      • (iv) subsequent oxidation of a compound of formula (IX), (IX)″, (IX)* or (IX)*″ (purified or not) with tert-butyl peroxide (1.5 eq) followed by protecting group deprotection.
  • In one embodiment, 1H-tetrazole is added to a compound of formula (III) or formula (IV) in ˜30 min (for example, 4 portions; for example, one added every ten minutes). As used in this embodiment, ˜30 min means + or −10 minutes, 20-40 minutes.
  • In another embodiment, a compound of formula (V) is added and reacted with a compound of formula (III) or a compound of formula (IV), forming a compound of formula (VI) or (VI)″, to which a compound of formula (VII) or formula (VIII) is added before the addition of imidazolium triflate.
  • In another embodiment, the reaction mixture containing the compound of formula (VI) or (VI)″ is cooled to 0° C. before the addition of a compound of formula (VII) or formula (VIII).
  • In one embodiment, the protecting group is cyanoethyl.
  • In another embodiment, deprotection is performed with triethylamine (TEA).
  • In a preferred embodiment, the protecting group is cyanoethyl and deprotection is with triethylamine (TEA).
  • In one embodiment, the coupling agent used with a compound of formula (III) or formula (IV) and a compound of formula (V) is at 2.1 equivalents, the compound of formula (III) or formula (IV) is at 2.0 equivalents, the compound of formula (V) is at 2.1 equivalents, the compound of formula (VII) or formula (VIII) is at 1.0 equivalent and the oxidizing agent for the compound of formula (IX), (IX)″, (IX)* or (IX)*″ is at 1.5 equivalent.
  • In one embodiment, imidazolium triflate is added with the compound of formula (VII) or the compound of formula (VIII) to the same reaction mixture produced by the reaction of compound of formula (V) with the compound of formula (III) or the compound of formula (IV).
  • The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way, the present invention being defined by the claims.
  • In the examples, the following terms have the designated meaning:
  • eq=equivalents;
  • ES TOF-MS=electrospray time of flight mass spectroscopy;
  • h=hour;
  • H=hydrogen atom;
  • Hz=Hertz; MHz=megaHertz;
  • min=minute;
  • M=molar;
  • NMR=nuclear magnetic resonance;
  • rt=room temperature;
  • TEA=triethylamine;
  • v=volume.
    • Example 1: General Procedure for the Synthesis of Phosphotriester IX
  • To a solution of III or IV (2.0 eq) in anhydrous methylene chloride (0.4 M) was added 2-cyanoethyl N,N,N,N-tetraisopropylphosphordiamidite V (2.1 eq) at rt. 1H-tetrazole (2.1 eq) was then added in four portions over 20 minutes and the reaction mixture stirred at rt for 1 h. After 1 h, the resulting phosphoramidite VI or VI″ was formed. The reaction mixture was cooled to 0° C. and imidazoquinoline VII or oxoadenine VIII (1.0 eq) and imidazolium triflate (1.5 eq) were added. The reaction mixture was allowed to warm up to rt. The reaction was usually completed after 1 hour at rt. The resulting phosphite IX, IX″, IX* or IX*″ can be purified at this stage or subsequently oxidized without isolation.
    • Example 2: General Procedure for the Oxidation of IX
  • The phosphotriester IX, IX″, IX* or IX*″ (purified or not) in a solution of methylene chloride was oxidized by addition of t-butyl hydroperoxide (1.5 eq) to the reaction mixture and stirring at rt for 30 min. After completion of the oxidation, the reaction mixture was concentrated under vacuum and purified by chromatography on silica gel. The resulting protected phosphotriester was dissolved in acetonitrile (0.06 M). Triethylamine (acetonitrile:TEA 1:0.35 v:v) was added and the reaction mixture stirred at rt for 6 to 18 hours. Once the deprotection was complete, the reaction mixture was filtered over a Buchner filter and the isolated solid rinsed with acetonitrile and dried under high vacuum. The reaction mixture can also be purified by chromatography on silica gel.
    • Example 3: Synthesis of 4-amino-1-[2-(1,2-di-O-palmitoyl-sn-glycero-3-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline, Compound (Ia)
  • R1=n-Bu, Z═(CH2)2, n=0, R2=R3=n-C15H31CO
  • Figure US20220119428A1-20220421-C00049
  • Phosphotriester IXa was prepared in 93% yield by reacting di-O-palmitoyl glycerol IIa with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXa was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ia in 71% yield.
  • 1H NMR (CDCl3/CD3OD, 400 MHz): δ 8.23 (bs, IH), 7.39 (t, IH), 7.22 (bs, IH), 6.93 (bs, IH), 5.25 (m, IH), 4.70 (bs, 2H), 4.60 (bs, 2H), 4.42 (dd, IH), 4.19 (dd, IH), 4.04 (t, 2H), 3.06 (bs, 2H), 2.32 (m, 4H), 1.96 (m, 2H) 1.59 (m, 6H), 1.26 (m, 48H), 1.07 (t, 3H), 0.88 (m, 6H); Positive ES TOF-MS calcd for [M+H]+ 915.6340; found 915.6309.
    • Example 4: Synthesis of 4-amino-1-[2-(1,2-di-O-palmitoyl-sn-glycero-3-phospho)ethyl]-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline, Compound (Ib)
  • R1═CH2OEt, Z═(CH2)2, n=0, R2=R3=n-C15H31CO
  • Figure US20220119428A1-20220421-C00050
  • Phosphotriester IXb was prepared in 99% yield by reacting di-O-palmitoyl glycerol IIIa with V followed by addition of imidazoquinoline VIIb and imidazolium triflate as described in example 1. IXb was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ib in 73% yield.
  • 1H NMR (CDCl3/CD3OD, 400 MHz): δ 8.05 (bs, 1H), 7.29 (t, 1H), 7.09 (bs, 1H), 6.78 (bs, 1H), 5.11 (m, 1H), 4.80 (bs, 4H), 4.60 (bs, 2H), 4.28 (dd, 1H), 4.07 (dd, 1H), 3.90 (t, 2H), 3.54 (dd, 2H), 2.18 (m, 4H), 1.59 (m, 4H), 1.16 (m, 51H), 0.76 (m, 6H). Positive ES TOF-MS calcd for [M+H]+ 917.6132; found 917.6162.
    • Example 5: Synthesis of 4-amino-1-[2-(1,2-di-O-hexadecyl-sn-glycero-3-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline, Compound (Ic)
  • R1=n-Bu, Z═(CH2)2, n=0, R2=R3=n-C15H31
  • Figure US20220119428A1-20220421-C00051
  • Phosphotriester IXc was prepared in 97% yield by reacting di-O-hexadecyl glycerol IIIc with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXc was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ic in 71% yield.
  • 1H NMR (CDCl3/CD3OD, 400 MHz): δ 8.23 (bs, 1H), 7.40 (t, 1H), 7.18 (bs, 1H), 6.96 (bs, 1H), 4.70 (bs, 2H), 4.60 (bs, 2H), 3.95 (t, 2H), 3.50 (mm, 7H), 4.04 (t, 2H), 3.03 (bs, 2H), 1.94 (m 2H), 1.56 (m, 6H), 1.26 (m, 52H), 1.06 (t, 3H), 0.88 (t, 6H). Positive ES TOF-MS calcd for [M+H]+ 885.6598. found 885.8304.
    • Example 6: Synthesis of 4-amino-1-[2-(1,2-di-O-lauroyl-sn-glycero-3-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline, Compound (Id)
  • R1=n-Bu, Z═(CH2)2, n=0, R2=R3=n-C11H23CO
  • Figure US20220119428A1-20220421-C00052
  • Phosphotriester IXd was prepared in 79% yield by reacting di-O-lauroyl glycerol IIId with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXd was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Id in 77% yield.
  • 1H NMR (CDCl3/CD3OD, 400 MHz): δ 8.09 (bs, 1H), 7.30 (t, 1H), 7.09 (bs, 1H), 6.81 (bs, 1H), 5.12-5.17 (m, 1H), 4.22-4.76 (m, 4H), 4.31 (dd, 1H), 4.11 (dd, 1H), 3.93 (t, 2H, 1H), 2.93 (bs, 2H), 2.20 (dd, 4H), 1.84 (m, 2H), 1.42-1.49 (m, 6H), 1.15 (m, 34H), 0.96 (t, 3H), 0.78 (t, 6H). Negative ES TOF-MS calc for [M−H]− 801.4931; found 801.4741.
    • Example 7: Synthesis of 4-amino-1-[2-(1,2-di-O-myristoyl-sn-glycero-3-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline, Compound (Ie)
  • R1=n-Bu, Z═(CH2)2, n=0, R2=R3=n-C13H27CO
  • Figure US20220119428A1-20220421-C00053
  • Phosphotriester IXe was prepared in 62% yield by reacting di-O-myristoyl glycerol IIe with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXe was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ie in 89% yield.
  • 1H NMR (CDCl3/CD3OD, 400 MHz): δ 8.17 (bs, 1H), 7.39 (bs, 1H), 7.17 (bs, 1H), 6.91 (bs, 1H), 5.24 (m, 1H), 4.80 (bs, 2H), 4.60 (bs, 2H), 4.41 (dd, 1H), 4.19 (dd, 1H), 4.03 (t, 2H), 2.99 (bs, 2H), 2.30 (m, 4H), 1.94 (bs, 2H), 1.57 (m, 6H), 1.25 (m, 40H), 1.05 (t, 3H), 0.88 (m, 6H). Positive ES TOF-MS calcd for [M+H]+ 857.5558; found 857.5565.
    • Example 8: Synthesis of 4-amino-1-[2-(1,2-di-O-oleoyl-sn-glycero-3-phospho)ethyl]-2-n-butyl-1H-imidazo[4,5-c]quinoline, Compound (If)
  • R1=n-Bu, Z═(CH2)2, n=0, R2=R3═(CH2)7CH═CH(CH2)7CH3
  • Figure US20220119428A1-20220421-C00054
  • Phosphotriester IXf was prepared in 92% yield by reacting di-O-oleoyl glycerol IIIf with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IXf was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline If in 75% yield.
  • 1H NMR (400 MHz, CDCl3/CD3OD) δ 8.18 (bs, 1H), 7.39 (bs, 1H), 7.18 (bs, 1H), 6.92 (bs, 1H), 5.33 (m, 4H), 5.25 (m, 1H), 4.80 (bs, 2H), 4.60 (bs, 2H), 4.41 (dd, J=3.2, 12.0 Hz, 1H), 4.19 (dd, J=6.4, 12.0 Hz, 1H), 4.03 (t, J=6.0 Hz, 2H), 3.01 (bs, 2H), 2.30 (m, 4H), 1.98 (m, 4H), 1.57 (m, 6H), 1.27 (m, 40H), 1.05 (t, J=7.2, 3H), 0.88 (m, 6H); negative ES TOF-MS calc for [M−H]− 965.6497, found 965.6498.
    • Example 9: Synthesis of 4-amino-1-[2-O-(ethylcholestero-3-phospho)ethyl]-2-n-butyl-1H-imidazo[4.5-c]quinoline, Compound (Ig)
  • R1=n-Bu, Z═(CH2)2, n=1
  • Figure US20220119428A1-20220421-C00055
  • Phosphotriester IX″a was prepared in 99% yield by reacting ethyl cholesterol IVa with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IX″a was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ig in 44% yield.
  • 1H NMR (400 MHz, CDCl3/CD3OD) δ 10.17 (bs, 1H), 9.90 (bs, 0.5H), 8.40 (bs, 0.5H), 8.08 (d, 1H), 7.45 (bs, 1H), 7.29 (t, 1H), 7.02 (t, 1H), 6.86 (d, 1H), 6.11 (bs, 1H), 5.30 (bs, 2H), 4.95-4.40 (m, 4H), 4.02 (d, 2H), 3.68 (t, 2H), 3.3-2.8 (m, 3H), 2.36 (d, 1H), 2.18 (t, 1H), 2.0-1.8 (m, 8H), 1.4-0.8 (m, 39H), 0.68 (s, 3H). Positive ES TOF-MS calc for [M+H]+ 777.5084; found 777.6999.
    • Example 10: Synthesis of 4-amino-1-[2-O-(butylcholestero-3-phospho)ethyl]-2-n-butyl-1H-imidazo[4.5-c]quinoline, Compound (Ih)
  • R1=n-Bu, Z═(CH2)2, n=1
  • Figure US20220119428A1-20220421-C00056
    Figure US20220119428A1-20220421-C00057
  • Phosphotriester IX″b was prepared in 96% yield by reacting butyl cholesterol IVb with V followed by addition of imidazoquinoline VIIa and imidazolium triflate as described in example 1. IX″b was oxidized and deprotected following the procedure described in example 2 to give phospholipidated imidazoquinoline Ih in 56% yield.
  • 1H NMR (400 MHz, CDCl3/CD3OD) δ 8.01 (bs, 1H), 7.31 (bs, 1H), 7.04 (bs, 1H), 6.88 (bs, 1H), 5.32 (m, 2H), 4.82 (bs, 2H), 4.53 (bs, 2H), 3.92 (m, 2H), 3.48 (m, 2H), 3.2-2.8 (m, 2H), 2.32 (m, 1H), 2.16 (m, 1H), 1.62-2.10 (m, 11H), 0.97-1.60 (2m, 9H), 0.86-0.95 (m, 9H), 0.68 (s, 3H); negative ES TOF-MS calc for [M−H]− 803.5240, found 803.5923.
    • Example 11: Synthesis of 6-amino-2-butoxy-9-[N-(2-(1,2-di-O-palmitoyl-sn-glycero-3-phosphoramido)ethyl)-4-piperidinylmethyl]-8-hydroxypurine, Compound (IIa)
  • R=n-butoxy, d=1, X═CH, Y═N, m=2, n=0, R2=R3=n-C15H31CO
  • Figure US20220119428A1-20220421-C00058
  • Phosphotriester IX*a was prepared in 33% yield by reacting di-O-palmitoyl glycerol IIIa with V followed by addition of oxoadenine VIIIa and imidazolium triflate as described in example 1. IX*a was oxidized and deprotected following the procedure described in example 2 to give phospholipidated oxoadenine IIa in 56% yield.
  • 1H NMR (CDCl3/CD3OD, 400 MHz): δ 5.17 (bs, IH), 4.32 (dd, IH), 4.20-4.09 (m, 5H), 3.98 (br t, 2H), 3.69 (br d, 3H), 3.23 (br s, IH), 1.86 (br s, 4H), 1.69 (m, 2H), 1.53 (br s, 4H), 1.42 (dd, 2H), 1.20 (m, 48H), 0.91 (t, 3H), 0.83 (t, 6H). Negative ES TOF-MS calc for [M−H]− 993.6768; found 993.6782.
    • Example 12: Synthesis of 6-amino-2-butoxy-9-[N-(2-(1,2-di-O-oleoyl-sn-glycero-3-phosphoramido)ethyl)-4-piperidinylmethyl]-8-hydroxypurine, Compound (IIb)
  • R=n-butoxy, d=1, X═CH, Y═N, m=2, n=0, R2=R3═(CH2)7CH═CH(CH2)7CH3
  • Figure US20220119428A1-20220421-C00059
  • Phosphotriester IX*b was prepared in 58% yield by reacting di-O-oeloyl glycerol IIIf with V followed by addition of oxoadenine VIIIa and imidazolium triflate as described in example 1. IX*b was oxidized and deprotected following the procedure described in example 2 to give phospholipidated oxoadenine IIb in 73% yield.
  • 1H NMR (CDCl3/CD3OD, 400 MHz): δ 5.3 (m, 4H), 5.23 (m, 1H), 4.37 (dd, 1H), 4.20 (m, 5H), 4.04 (t, 2H), 3.70 (m, 4H), 3.27 (bs, 2H), 2.74 (m, 2H), 2.30 (m, 5H), 2.00 (m, 12H), 1.75 (m, 2H), 1.60 (bs, 4H), 1.48 (m, 2H), 1.30 (m, 40H), 0.97 (t, 3H), 0.88 (t, 3H). Negative ES TOF-MS calc for [M−H]− 1045.7082; found 1045.2163.

Claims (13)

1. A compound of formula (II):
Figure US20220119428A1-20220421-C00060
wherein
R4 is C1-6alkyl;
d is 1;
m is 2;
A is
Figure US20220119428A1-20220421-C00061
wherein
R2 is H or a straight or branched, optionally unsaturated, C4-C24 alkyl, or a straight or branched, optionally unsaturated, C4-C24, acyl;
R3 is a straight or branched, optionally unsaturated, C4-C24 alkyl or a straight or branched, optionally unsaturated, C4-C24 acyl;
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein R2 and R3 are —C(O)-nC11H23.
3. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein R2 and R3 are —C(O)-nC13H27.
4. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein R2 and R3 are —C(O)-nC15H31.
5. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein R2 and R3 are —C(O)—(CH2)7CH═CH(CH2)7CH3.
6. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 2, wherein n is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
7. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 3, wherein n is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
8. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 4, wherein n is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
9. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 5, wherein n is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
10. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein A is:
Figure US20220119428A1-20220421-C00062
11. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein A is:
Figure US20220119428A1-20220421-C00063
12. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein A is:
Figure US20220119428A1-20220421-C00064
13. The compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein A is:
Figure US20220119428A1-20220421-C00065
US17/566,247 2015-12-14 2021-12-30 Phospholipidation of imidazoquinolines and oxoadenines Pending US20220119428A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/566,247 US20220119428A1 (en) 2015-12-14 2021-12-30 Phospholipidation of imidazoquinolines and oxoadenines

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562266858P 2015-12-14 2015-12-14
PCT/EP2016/080647 WO2017102654A1 (en) 2015-12-14 2016-12-12 Phospholipidation of imidazoquinolines and oxoadenines
US201816060142A 2018-06-07 2018-06-07
US16/989,235 US11248012B2 (en) 2015-12-14 2020-08-10 Phospholipidation of imidazoquinolines and oxoadenines
US17/566,247 US20220119428A1 (en) 2015-12-14 2021-12-30 Phospholipidation of imidazoquinolines and oxoadenines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/989,235 Continuation US11248012B2 (en) 2015-12-14 2020-08-10 Phospholipidation of imidazoquinolines and oxoadenines

Publications (1)

Publication Number Publication Date
US20220119428A1 true US20220119428A1 (en) 2022-04-21

Family

ID=57629576

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/060,142 Active US10774099B2 (en) 2015-12-14 2016-12-12 Phospholipidation of imidazoquinolines and oxoadenines
US16/989,235 Active US11248012B2 (en) 2015-12-14 2020-08-10 Phospholipidation of imidazoquinolines and oxoadenines
US17/566,247 Pending US20220119428A1 (en) 2015-12-14 2021-12-30 Phospholipidation of imidazoquinolines and oxoadenines

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US16/060,142 Active US10774099B2 (en) 2015-12-14 2016-12-12 Phospholipidation of imidazoquinolines and oxoadenines
US16/989,235 Active US11248012B2 (en) 2015-12-14 2020-08-10 Phospholipidation of imidazoquinolines and oxoadenines

Country Status (10)

Country Link
US (3) US10774099B2 (en)
EP (1) EP3390416B1 (en)
JP (1) JP2019505489A (en)
CN (1) CN108368138A (en)
BE (1) BE1024380B1 (en)
BR (1) BR112018011780A2 (en)
CA (1) CA3008054A1 (en)
ES (1) ES2831162T3 (en)
MX (1) MX2018007321A (en)
WO (1) WO2017102654A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1024380B1 (en) * 2015-12-14 2018-02-12 Glaxosmithkline Biologicals Sa PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINS
EP3510036B1 (en) 2016-09-07 2021-07-21 GlaxoSmithKline Biologicals SA Imidazoquinoline derivatives and their use in therapy
EP3922266A4 (en) * 2019-02-08 2023-02-01 Progeneer Inc. Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same
WO2020162705A1 (en) * 2019-02-08 2020-08-13 성균관대학교산학협력단 Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same
MX2021014353A (en) 2019-05-23 2022-02-21 The Univ Of Montana Vaccine adjuvants based on tlr receptor ligands.
CN112778372A (en) * 2019-11-11 2021-05-11 苏州泽璟生物制药股份有限公司 Imidazoquinoline substituted phosphate agonist and preparation method and application thereof
JP2023536954A (en) * 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド Conjugate of Toll-like Receptor 7 or 8 Agonist with Temporarily Inactivated Activation Site and Functional Drug, and Use of the Same
JP2023536945A (en) * 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド Kinetic Adjuvant Ensemble
CN116322751A (en) * 2020-08-04 2023-06-23 蛋白科技先锋 mRNA vaccine comprising an adjuvant capable of kinetic control

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264394B (en) * 2008-10-24 2014-01-01 葛兰素史密丝克莱恩生物有限公司 Lipidated imidazoquinoline derivatives
AU2010279299B2 (en) 2009-08-07 2015-10-01 Glaxosmithkline Biologicals Sa Lipidated oxoadenine derivatives
CN102372711B (en) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 Imidazo quinoline PI3K and mTOR (mammalian target of rapamycin) dual inhibitor
US20140242112A1 (en) * 2012-11-30 2014-08-28 Glaxosmithkline Biologicals S.A. Novel vaccine
BE1024380B1 (en) * 2015-12-14 2018-02-12 Glaxosmithkline Biologicals Sa PHOSPHOLIPIDATION OF IMIDAZOQUINOLINES AND OXOADENINS
US10351582B2 (en) * 2015-12-14 2019-07-16 Glaxosmithkline Biologicals, S.A. Pegylated imidazoquinolines

Also Published As

Publication number Publication date
BR112018011780A2 (en) 2018-12-04
CA3008054A1 (en) 2017-06-22
US10774099B2 (en) 2020-09-15
BE1024380A1 (en) 2018-02-05
US11248012B2 (en) 2022-02-15
CN108368138A (en) 2018-08-03
JP2019505489A (en) 2019-02-28
US20180273560A1 (en) 2018-09-27
EP3390416A1 (en) 2018-10-24
WO2017102654A1 (en) 2017-06-22
ES2831162T3 (en) 2021-06-07
US20210024553A1 (en) 2021-01-28
EP3390416B1 (en) 2020-08-19
MX2018007321A (en) 2018-09-06
BE1024380B1 (en) 2018-02-12

Similar Documents

Publication Publication Date Title
US11248012B2 (en) Phospholipidation of imidazoquinolines and oxoadenines
BE1024865B1 (en) IMIDAZOQUINOLEINE DERIVATIVES
RU2266909C2 (en) Water-soluble azole compounds and method for their preparing
NL1031741C2 (en) Purine derivatives.
US6903219B2 (en) Process to produce derivatives from UK-2A derivatives
ES2395137T3 (en) Azapeptide derivatives as HIV protease inhibitors
US8921328B2 (en) E-selectin antagonists
RU2503673C2 (en) Novel 5-fluorouracil derivative
JP6860559B2 (en) EP4 antagonist
WO2010120112A2 (en) Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
JPH01311091A (en) Water-soluble prodrug
BRPI0717089A2 (en) QUINOLINONE DERIVATIVES
US7214794B2 (en) Ceramide analogs, process for their preparation and their use as antitumor agents
US6458961B1 (en) Water soluble prodrugs of azole compounds
KR101872264B1 (en) New type of cytidine derivative dimer and application thereof
JP3009716B2 (en) New camptothecin derivatives
US20100179116A1 (en) Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof
CN115340526B (en) Phthalimide compound, pharmaceutical composition, preparation method and application thereof
JP2019524654A (en) A new type of taxane compound, its production method and application
CN114409653A (en) Bridged ring pyrimidine-fused ring compound and application thereof
CA2914262A1 (en) Novel pyrrole derivatives
KR20130018548A (en) Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
SE433852B (en) PROCEDURE FOR THE PRODUCTION OF CEPHALOSPORINE DERIVATIVES
CZ650090A3 (en) Process for preparing 1,1-dioxopenicillanoylmethyl -6-/2-/2-imidazolidinon-1-yl-carbonylamino/-2-phenylacetamido/penicillate
EP0140949A1 (en) Novel cephalosporin derivatives, pharmaceutical compositions containing the same, their use in therapy as antibiotics and a process for the preparation of the novel compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAZIN-LEE, HELENE G.;BESS, LAURA S;JOHNSON, DAVID A.;SIGNING DATES FROM 20170412 TO 20170429;REEL/FRAME:058510/0347

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION